Are you Dr. Ohanian?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 47 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-7305Fax+1 713-792-4297
Summary
- Dr. Maro Ohanian, DO is an oncologist in Houston, Texas. She is currently licensed to practice medicine in Texas, Florida, and Oklahoma. She is affiliated with University of Texas M.D. Anderson Cancer Center.
Education & Training
Texas A&M College of Medicine-Scott and White Medical Center (Temple)Fellowship, Hematology and Medical Oncology, 2009 - 2011
University of Texas Medical Branch HospitalsResidency, Internal Medicine, 2006 - 2009
Texas College of Osteopathic MedicineClass of 2006
Certifications & Licensure
FL State License 2021 - Present
TX State License 2009 - 2024
OK State License 2020 - 2021- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML Start of enrollment: 2016 May 01
- Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia Start of enrollment: 2017 Aug 09
- Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers Start of enrollment: 2018 Sep 19
- Join now to see all
Publications & Presentations
PubMed
- 111 citationsComplex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials.Timothy A Yap, Naval Daver, Mikhila Mahendra, Jixiang Zhang, Carlos Kamiya-Matsuoka
Nature Medicine. 2023-01-01 - 40 citationsAzacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalati...Alexandre Bazinet, Faezeh Darbaniyan, Elias Jabbour, Guillermo Montalban-Bravo, Maro Ohanian
The Lancet. Haematology. 2022-10-01 - 114 citationsOutcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens.Curtis Lachowiez, Sanam Loghavi, Tapan M. Kadia, Naval Daver, Gautam Borthakur
Blood Advances. 2020-04-14
Authored Content
- Clinical Experience of Venetoclax Combinations for Relapsed/Refractory Myeloid MalignanciesOctober 2017
- The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II TrialOctober 2017
- Randomized Phase II Study of Guadecitabine (SGI-110) Based Regimens Comparing Guadecitabine 5 Days (SGI5), 10 Days (SGI10), 5 Days + Idarubicin (SGI5 + Ida), and 5 Days + Cladribine (SGI5 + Clad), in Previously Untreated Patients ≥ 70 Years with Acute Myeloid Leukemia (AML)–a Bayesian DesignOctober 2017
Press Mentions
What’s New in Leukemia Research?May 29th, 2024- HM43239 Demonstrates Durable Clinical Benefit in Acute Myeloid LeukemiaDecember 13th, 2021
